{"id":1445,"date":"2010-02-24T17:12:59","date_gmt":"2010-02-24T22:12:59","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/wednesday-february-24-avandia-roundup-aha-acc-publish-science-advisory-on-tzds-glaxosmithkline-white-paper\/"},"modified":"2011-07-19T17:45:02","modified_gmt":"2011-07-19T21:45:02","slug":"wednesday-february-24-avandia-roundup-aha-acc-publish-science-advisory-on-tzds-glaxosmithkline-white-paper","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/02\/24\/wednesday-february-24-avandia-roundup-aha-acc-publish-science-advisory-on-tzds-glaxosmithkline-white-paper\/","title":{"rendered":"Wednesday February 24 Avandia Roundup: AHA &amp; ACC Publish Science Advisory on TZDs; GlaxoSmithKline White Paper"},"content":{"rendered":"<p><strong>AHA\/ACC Publish Science Advisory on Thiazolidinedione Drugs:<\/strong> Apparently in response to the renewed controversy over rosiglitazone (Avandia), the AHA and the ACC published<a href=\"http:\/\/circ.ahajournals.org\/cgi\/reprint\/CIR.0b013e3181d34114\"> a science advisory on thiazolidinedione drugs and cardiovascular risks<\/a>. The advisory contains a highly detailed and balanced analysis of the issue. The authors, led by Sanjay Kaul, conclude that &#8220;an association between rosiglitazone and IHD outcomes has not yet been firmly established,&#8221; but acknowledges that &#8220;sufficient evidence has emerged to raise concerns about a potential adverse effect.&#8221;<\/p>\n<p><strong>GlaxoSmithKline&nbsp;White Paper:<\/strong> GlaxoSmithKline published a&nbsp;<a href=\"http:\/\/www.gsk.com\/media\/GSK-White-Paper-Avandia-23-Feb-2010.pdf\">30 page White Paper<\/a>&nbsp;in response to<a href=\"http:\/\/cardioexchange.org\/blogPost?postId=459\"> the Senate Finance Committee report<\/a> released on Saturday. The senate report &#8220;mischaracterizes and distorts&#8221; GSK&#8217;s efforts to monitor the safety and efficacy of Avandia, the document claims.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AHA\/ACC Publish Science Advisory on Thiazolidinedione Drugs: Apparently in response to the renewed controversy over rosiglitazone (Avandia), the AHA and the ACC published a science advisory on thiazolidinedione drugs and cardiovascular risks. The advisory contains a highly detailed and balanced analysis of the issue. The authors, led by Sanjay Kaul, conclude that &#8220;an association between [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1445","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1445"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1445\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}